J Biol Chem, Vol. 275, Issue 3, 1829-1838, January 21, 2000
CD44 Interaction with Tiam1 Promotes Rac1 Signaling and
Hyaluronic Acid-mediated Breast Tumor Cell Migration*
Lilly Y. W.
Bourguignon
,
Hongbo
Zhu,
Lijun
Shao, and
You Wei
Chen
From the Department of Cell Biology and Anatomy, School of
Medicine, University of Miami, Miami, Florida 33101
 |
ABSTRACT |
In this study we have explored the interaction
between CD44 (the hyaluronic acid (HA)-binding receptor) and Tiam1 (a
guanine nucleotide exchange factor) in metastatic breast tumor cells
(SP1 cell line). Immunoprecipitation and immunoblot analyses indicate that both the CD44v3 isoform and the Tiam1 protein are expressed in SP1
cells and that these two proteins are physically associated as a
complex in vivo. Using an Escherichia
coli-derived calmodulin-binding peptide-tagged Tiam1 fragment
(i.e. the NH2-terminal pleckstrin homology
(PHn) domain and an adjacent protein interaction domain designated as
PHn-CC-Ex, amino acids 393-738 of Tiam1) and an in vitro
binding assay, we have detected a specific binding interaction between
the Tiam1 PHn-CC-Ex domain and CD44. Scatchard plot analysis indicates
that there is a single high affinity CD44 binding site in the PHn-CC-Ex
domain of Tiam1 with an apparent dissociation constant
(Kd) of 0.2 nM, which is comparable
with CD44 binding (Kd = ~0.13 nM) to
intact Tiam1. These findings suggest that the PHn-CC-Ex domain is the
primary Tiam1-binding region for CD44. Most importantly, the binding of
HA to CD44v3 of SP1 cells stimulates Tiam1-catalyzed Rac1 signaling and
cytoskeleton-mediated tumor cell migration. Transfection of SP1 cells
with Tiam1cDNA promotes Tiam1 association with CD44v3 and
up-regulates Rac1 signaling as well as HA/CD44v3-mediated breast tumor
cell migration. Co-transfection of SP1 cells with PHn-CC-Ex cDNA
and Tiam1 cDNA effectively inhibits Tiam1 association with CD44 and
efficiently blocks tumor behaviors. Taken together, we believe that the
linkage between CD44v3 isoform and the PHn-CC-EX domain of Tiam1 is
required for HA stimulated Rac1 signaling and cytoskeleton-mediated
tumor cell migration during breast cancer progression.
 |
INTRODUCTION |
The transmembrane glycoprotein CD44 isoforms are all major
hyaluronic acid (HA)1 cell
surface receptors that exist on many cell types, including macrophages,
lymphocytes, fibroblasts, and epithelial cells (1-6). Because of their
widespread occurrence and their role in signal transduction, CD44
isoforms have been implicated in the regulation of cell growth and
activation as well as cell-cell and cell-extracellular matrix
interactions (1-7). One of the distinct features of CD44 isoforms is
the enormous heterogeneity in the molecular masses of these proteins.
It is now known that all CD44 isoforms are encoded by a single gene
that contains 19 exons (8). Of the 19 exons, 12 exons can be
alternatively spliced (8). Most often, the alternative splicing occurs
between exons 5 and 15, leading to an insertion in tandem of one or
more variant exons (v1-v10 (exon 6-exon 14) in human cells) within the
membrane-proximal region of the extracellular domain (8). The variable
primary amino acid sequence of different CD44 isoforms is further
modified by extensive N- and O-glycosylations and
glycosaminoglycan additions (9-12). In particular, CD44v3-containing
isoforms have a heparin sulfate addition at the membrane-proximal
extracellular domain of the molecule that confers the ability to bind
heparin sulfate-binding growth factors (9, 10). Cell surface expression
of CD44v isoforms changes profoundly during tumor metastasis,
particularly during the progression of various carcinomas including
breast carcinomas (13-17). In fact, CD44v isoform expression has been used as an indicator of metastasis.
It has been shown that interaction between the cytoskeletal protein,
ankyrin, and the cytoplasmic domain of CD44 isoforms plays an important
role in CD44 isoform-mediated oncogenic signaling (6, 18, 19).
Specifically, the ankyrin-binding domain (e.g. NGGNGTVEDRKPSEL between amino acids 306 and 320 in the mouse CD44 (20)
and NSGNGAVEDRKPSGL amino acids 304 and 318 in human CD44 (21)) is
required for the recruitment of Src kinase and the onset of tumor cell
transformation (21). Furthermore, HA binding to CD44 stimulates a
concomitant activation of p185HER2-linked tyrosine kinase
(linked to CD44s via a disulfide linkage) and results in a direct
cross-talk between two different signaling pathways (e.g.
proliferation versus motility/invasion) (22). In tumor
cells, the transmembrane linkage between CD44 isoform and the
cytoskeleton promotes invasive and metastatic-specific tumor phenotypes
(e.g. matrix degradation (matrix metalloproteinases) activities (23, 24), "invadopodia" formation (membrane
projections), tumor cell invasion, and migration) (23). These findings
strongly suggest that the interaction between CD44 isoform and the
cytoskeleton plays a pivotal role in the onset of oncogenesis and tumor progression.
The Rho family proteins (e.g. Rho, Rac, and Cdc42) are
members of the Ras superfamily of GTP-binding proteins structurally related to but functionally distinct from Ras itself (25, 26). They are
associated with changes in the membrane-linked cytoskeleton (26). For
example, activation of RhoA, Rac1, and Cdc42 have been shown to produce
specific structural changes in the plasma membrane-cytoskeleton
reorganization leading to membrane ruffling, lamellipodia, filopodia,
and stress fiber formation (26). The coordinated activation of these
GTPases is considered to be a possible mechanism underlying cell
motility, an obvious prerequisite for metastasis (27-29). In
particular, Rac1 activation is known to initiate oncogenic signaling
pathways that promote cell shape changes (33, 34), influence actin
cytoskeleton organization (33, 34), and stimulate gene expression
(35-37). The question of whether Rac1 activation is also involved in
CD44v3-related cytoskeleton function that results in the metastatic
phenotypes (e.g. tumor cell migration) of breast tumor cells
remains to be answered.
Tiam1 (T lymphoma invasion and
metastasis 1) has been identified as an
oncogene because of its ability to activate Rho-like GTPases during
malignant transformation (38, 39). Specifically, Tiam1 is capable of
activating Rac1 in vitro as a guanine nucleotide exchange
factor and inducing membrane cytoskeleton-mediated cell shape changes,
cell adhesion, and cell motility (34, 40-42). It also acts as a
Rac-specific guanine nucleotide exchange factor in vivo and
induces an invasive phenotypes in lymphoma cells (40). These findings
have prompted several research groups to investigate the mechanisms
involved in the regulation of Tiam1. For example, addition of certain
serum-derived lipids (e.g. sphingosine-1-phosphate and
lysophosphatidic acid) to T-lymphoma cells promotes Tiam1-mediated Rac1
and Cdc42 signaling and T-lymphoma cell invasion (43). Tiam1 has also
been found to be phosphorylated by protein kinase C in Swiss 3T3
fibroblasts stimulated by lysophosphatidic acid (44) and
platelet-derived growth factor (45). Most recently, Exton and
co-workers (46) demonstrate that phosphorylation of Tiam1 by
Ca2+/calmodulin-dependent protein kinase II
(but not protein kinase C) regulates Tiam1-catalyzed GDP/GTP exchange
activity in vitro. These findings support the notion that
posttranslational modifications of Tiam1 by certain serine/threonine
kinase(s) during surface receptor-mediated activation may play an
important role in Tiam1-Rac1 signaling. Tiam1 transcript has been
detected in breast cancer cells (39). However, it is not known at the
present time whether there is any structural and functional
relationship(s) between Tiam1-Rac1 signaling and CD44v3-mediated
invasive and metastatic processes of breast cancer cells.
In this paper, using a variety of biochemical, molecular biological,
and immunocytochemical techniques, we have found that the cell adhesion
molecule, CD44v3 isoform, which binds directly to HA, is
closely associated with Tiam1 (in particular, the
NH2-terminal pleckstrin homology (PHn), a putative coiled
coil region (CC), and an additional adjacent region (Ex), designated as
PHn-CC-Ex domain of Tiam1) in SP1 breast tumor cells. Most importantly, HA binding to CD44v3 isoform stimulates Tiam1-specific
GDP/GTP exchange for Rho-like GTPases such as Rac1 and promotes
cytoskeleton-mediated tumor cell migration. These findings suggest that
a transmembrane interaction between CD44v3 and Tiam1 plays an important
role in promoting oncogenic signaling and tumor cell-specific
phenotypes required for HA-mediated breast tumor cell migration.
 |
MATERIALS AND METHODS |
Cell Culture--
Mouse breast tumor cells (e.g. SP1
cell line) (provided by Dr. Bruce Elliott, Department of Pathology, and
Biochemistry, Queen's University, Kingston, ON, Canada) were used in
this study. Specifically, SP1 cell line was derived from a spontaneous
intraductal mammary adenocarcinoma that arose in a retired female CBA/J
breeder in the Queen's University animal colony. These cells were
capable of inducing lung metastases by sequential passage of SP1 cells into mammary gland (47). These cells were cultured in RPMI 1640 medium
supplemented with 5-7% fetal calf serum, folic acid (290 mg/liter),
and sodium pyruvate (100 mg/liter). COS-7 cells were obtained from
American Type Culture Collection and grown routinely in Dulbecco's
modified Eagle's medium containing 10% fetal bovine serum, 1%
glutamine, 1% penicillin, and 1% streptomycin.
Antibodies and Reagents--
For the preparation of polyclonal
rabbit anti-Tiam1 antibody or rabbit anti-CD44v3 antibody, specific
synthetic peptides (
15-17 amino acids unique for the COOH-terminal
sequence of Tiam1 or the CD44v3 sequence) were prepared by the Peptide
Laboratories of Department of Biochemistry and Molecular Biology using
an Advanced Chemtech automatic synthesizer (model ACT350). These
Tiam1-related or CD44v3-related polypeptides were conjugated to
polylysine and subsequently injected into rabbits to raise the
antibodies, respectively. The anti-Tiam1-specific or
anti-CD44v3-specific antibody was collected from each bleed and stored
at 4 °C containing 0.1% azide. The anti-Tiam1 IgG or anti-CD44v3
IgG fraction was prepared by conventional DEAE-cellulose
chromatography, respectively. Mouse monoclonal anti-HA (hemagglutinin
epitope) antibody (clone 12 CA5) was purchased from Roche Molecular
Biochemicals. Mouse monoclonal anti-green fluorescent protein (GFP) was
purchased from PharMingen. Escherichia coli-derived
GST-tagged Rac1 was kindly provided by Dr. Richard A. Cerione (Cornell
University, Itheca, NY).
Cell Surface Labeling Procedures--
SP1 cells suspended in PBS
were surface labeled using the following biotinylation procedure.
Briefly, cells (107 cells/ml) were incubated with
sulfosuccinimidyl-6-(biotinamido)hexanoate (Pierce) (0.1 mg/ml) in
labeling buffer (150 µM NaCl, 0.1 M HEPES, pH
8.0) for 30 min at room temperature. Cells were then washed with PBS to
remove free biotin. Subsequently, the biotinylated cells were used for
anti-CD44v3-mediated immunoprecipitation as described previously (23).
These biotinylated materials precipitated by anti-CD44v3 antibody were
analyzed by SDS-polyacrylamide gel electrophoresis, transferred to the
nitrocellulose filters, and incubated with ExtrAvidin-peroxidase
(Sigma). After an addition of peroxidase substrate (Pierce), the blots
were developed using ECL chemiluminescence reagent (Amersham Pharmacia
Biotech) according to the manufacturer's instructions.
Immunoprecipitation and Immunoblotting Techniques--
SP1 cells
were solubilized in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100 buffer and immunoprecipitated
using rabbit anti-CD44v3 antibody or rabbit anti-Tiam1 antibody
followed by goat anti-rabbit IgG, respectively. The immunoprecipitated
material was solubilized in SDS sample buffer, electrophoresed, and
blotted onto the nitrocellulose. After blocking nonspecific sites with 3% bovine serum albumin, the nitrocellulose filter was incubated with
rabbit anti-Tiam1 antibody (5 µg/ml) or rabbit anti-CD44v3 antibody
(5 µg/ml), respectively, for 1 h at room temperature followed by
incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG
(1:10,000 dilution) at room temperature for 1 h. The blots were
developed using ECL chemiluminescence reagent (Amersham Pharmacia
Biotech) according to the manufacturer's instructions.
In some experiments, SP1 cells or COS cells (e.g.
untransfected or transfected by various Tiam1 cDNAs including the
full-length mouse Tiam1cDNA (FL1591) or HA-tagged
NH2-terminally truncated C1199 Tiam1cDNA or GFP-tagged
PHn-CC-ExcDNA or C1199Taim1cDNA plus GFP-tagged
PHn-CC-ExcDNA (as co-transfection) or vector only) were
immunoblotted with mouse anti-HA antibody (5 µg/ml) or anti-GFP antibody (5 µg/ml), respectively, for 1 h at room temperature followed by incubation with horseradish peroxidase-conjugated goat
anti-mouse IgG or goat anti-mouse IgG (1:10,000 dilution) at room
temperature for 1 h. The blots were developed using ECL chemiluminescence reagent (Amersham Pharmacia Biotech) according to the
manufacturer's instructions.
Cloning, Expression, and Purification of CD44 Cytoplasmic Domain
(CD44cyt) from E. coli--
The procedure for preparing the fusion
protein of the cytoplasmic domain of CD44 was the same as described
previously (48). Specifically, the cytoplasmic domain of human CD44
(CD44cyt) was cloned into pFLAG-AST using the PCR-based cloning
strategy. Using human CD44 cDNA as template, one PCR primer pair
(left, FLAG-EcoRI; right, FLAG-XbaI) was designed
to amplify complete CD44 cytoplasmic domain. The amplified DNA
fragments were one-step cloned into a pCR2.1 vector and sequenced. Then
the DNA fragments were cut out by double digestion with
EcoRI and XbaI and subcloned into EcoRI/XbaI double-digested pFLAG-AST (Eastman
Kodak Co., Rochester, NY) to generate FLAG-pCD44cyt construct. The
nucleotide sequence of FLAG/CD44cyt junction was confirmed by
sequencing. The recombinant plasmids were transformed to BL21-DE3 to
produce FLAG-CD44cyt fusion protein. The FLAG-CD44cyt fusion protein
was further purified by anti-FLAG M2 affinity gel column (Eastman Kodak
Co.). The nucleotide sequence of primers used in this cloning protocol
are: FLAG-EcoRI, 5'-GAGAATTCGAACAGTCGAAGAAGGTGTCTCTTAAGC-3',
and FLAG-XbaI, 5'-AGCTCTAGATTACACCCCAATCTTCAT-3'.
Expression Constructs--
Both the full-length mouse
Tiam1cDNA (FL1591) and the NH2-terminally truncated
Tiam1cDNA (C1199) were kindly provided by Dr. John G. Collard (The
Netherlands Cancer Institute, Amsterdam, The Netherlands).
Specifically, the full-length Taim1 (FL1591) cDNA was cloned into
the eukaryotic expression vector, pMT2SM. The
NH2-terminally truncated C1199 Tiam1 cDNA (carrying a
HA epitope tag at the 3' end) was cloned into the eukaryotic expression
vector, pUTSV1 (Eurogentec, Belgium). The Tiam1 fragment, PHn-CC-Ex
domain was cloned into calmodulin-binding peptide (CBP)-tagged vector (pCAL-n) (Stratagen) using the PCR-based cloning strategy. Using human
Tiam1 cDNA as a template, PHn-CC-Ex domain was amplified by PCR
with two specific primers (left, 5'-AACTCGAGATGAGTACCACCAACAGTGAG-3', and right, 5'-AAAAAGCTTTCAGCCATCTGGAACAGTGTCATC-3') linked with specific enzyme digestion site (XhoI or HindIII).
PCR product digested with XhoI and HindIII was
purified with QIAquick PCR Purification Kit (Qiagen). The PHn-CC-Ex
domain cDNA fragment was cloned into pCAL-n vector digested with
XhoI and HindIII. The inserted PHn-CC-Ex domain
sequence was confirmed by nucleotide sequencing analyses. The
recombinant plasmids were transformed to BL21-DE3 to produce CBP-tagged
PHn-CC-Ex fusion protein. This fusion protein was purified from
bacteria lysate by calmodulin affinity resin column (Sigma).
The PHn-CC-Ex domain cDNA fragment was also cloned into pEGFPN1
vector (CLONTECH) digested with XhoI and
HindIII to create GFP-tagged PHn-CC-Ex cDNA. The
inserted PHn-CC-Ex domain sequence was confirmed by nucleotide
sequencing analyses. This GFP-tagged PHn-CC-Ex domain cDNA was then
used for transient expression in SP1 cells as described below. The
molecular mass of the GFP-tagged PHn-CC-Ex is expressed as 68 kDa in
SP1 or COS-7 cells by SDS-polyacrylamide gel electrophoresis and
immunoblot analyses.
Cell Transfection--
To establish a transient expression
system, SP1 cells (or COS-7 cells) were transfected with various
plasmid DNAs (e.g. HA-tagged C1199 Tiam1cDNA, GFP-tagged
PHn-CC-ExcDNA, or HA-tagged C1199Tiam1cDNA plus GFP-tagged
PHn-CC-ExcDNA (as co-transfection) or vector alone) using
electroporation methods according to those procedures described previously (74). Briefly, SP1 cells were plated at a density of 2 × 106 cells/100-mm dish and transfected with 25 µg/dish
plasmid cDNA using electroporation at 230 V and 960 microfaraday
with a Gene Pulser (Bio-Rad). Transfected cells were grown in the
culture medium for at least 24-48 h. Various transfectants were then
analyzed for their protein expression (e.g. Tiam1-related
proteins) by immunoblot, GDP/GTP exchange reaction on Rac1, and tumor
cell migration assays as described below.
In Vitro Binding of Tiam1/Tiam1 Fragment to CD44--
Aliquots
(0.5-1 ng of protein) of purified FLAG-CD44cyt fusion protein bound to
Anti-FLAG M2 antibody immunoaffinity beads were incubated in 0.5 ml of
binding buffer (20 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 0.1% bovine serum albumin, and 0.05% Triton X-100) containing
various concentrations (10-800 ng/ml) of 125I-labeled
intact Tiam1 (purified from SP1 cells) (5000 cpm/ng protein) or
125I-labeled recombinant Tiam1 fragment (CBP-tagged
PHn-CC-Ex) at 4 °C for 4 h. Specifically, equilibrium binding
conditions were determined by performing a time course (1-10 h) of
125I-labeled Tiam1 (or CBP-tagged PHn-CC-Ex) binding to
CD44 at 4 °C. The binding equilibrium was found to be established
when the in vitro Tiam1 (or PHn-CC-Ex)-CD44 binding assay
was conducted at 4 °C after 4 h. Following binding, the
immunobeads were washed extensively in binding buffer, and the
bead-bound radioactivity was counted. Nonspecific binding was
determined using a 50-100-fold excess of unlabeled Tiam1 (or
PHn-CC-Ex) in the presence of the same concentration of
125I-labeled Tiam1 or 125I-labeled CBP-tagged
PHn-CC-Ex. Nonspecific binding, which was approximately 20% of the
total binding, was always subtracted from the total binding. Our
binding data are highly reproducible. The values expressed in Fig. 5
represent an average of triplicate determinations of three to five
experiments with a standard deviation less than ± 5%.
In some cases, 0.1 µg of surface biotinylated CD44v3 was incubated
with various Tiam1-related proteins (e.g. purified intact Tiam1, HA-tagged C1199, CBP-PHn-CC-Ex, or HA/CBP-coated beads) in the
presence and absence of 100-fold excess amount of CBP-PHn-CC-Ex at room
temperature in the binding buffer (20 mM Tris-HCl (pH 7.4),
150 mM NaCl, 0.1% bovine serum albumin, and 0.05% Triton X-100) for 1 h. After binding, biotinylated CD44v3 bound to the beads was analyzed by SDS-polyacrylamide gel electrophoresis, transferred to the nitrocellulose filters, and incubated with ExtrAvidin-peroxidase (Sigma). After an addition of peroxidase substrate (Pierce), the blots were developed using ECL
chemiluminescence reagent (Amersham Pharmacia Biotech) according to the
manufacturer's instructions.
Tiam1-mediated GDP/GTP Exchange for Rac1 Proteins--
Purified
E. coli-derived GST-tagged Rac1 (20pmol) was preloaded with
GDP (30 µM) in 10 µl of buffer containing 25 mM Tris-HCl (pH 8.0), 1 mM dithiothreitol, 4.7 mM EDTA, 0.16 mM MgCl2, and 200 µg/ml bovine serum albumin at 37 °C for 7 min. To terminate preloading procedures, additional MgCl2 was then added to the solution
(reaching a final concentration of 9.16 mM) as described previously (40, 49). Subsequently, 2 pmol of Tiam1 (in anti-Tiam1 (or
anti-HA or anti-CD44v3)-Sepharose bead-conjugated forms) isolated from
COS-7 cells (transfected with either the full-lengh Tiam1cDNA or
NH2-terminally truncated Tiam1cDNA) or SP1 cells
(transfected with various plasmid DNAs such as HA-tagged C1199
Tiam1cDNA, GFP-tagged PHn-CC-ExcDNA or HA-tagged
C1199Tiam1cDNA plus GFP-tagged PHn-CC-ExcDNA (as
co-transfection) or vector alone, grown in the presence or absence of
hyaluronic acid (100 µg/ml)) or control samples (nonspecific cellular
material associated with preimmune serum-conjugated Sepharose beads)
was preincubated with 2.5 µM [35S]GTP
S
(
1,250 Ci/mmol) (in the presence or absence of 2.25 µM GTP
S for 10 min followed by adding 2.5 pmol of GDP-loaded GST-tagged Rac1GTPase as described previously) (49). The amount of
[35S]GTP
S bound to Tiam1 (conjugated to
anti-Tiam1-Sepharose beads) or control sample (preimmune
serum-conjugated Sepharose beads) in the absence of Rac1GTPase was
subtracted from the original values. Data represent an average of
triplicates from three to five experiments. The standard deviation was
less than 5%.
Double Immunofluorescence Staining--
SP1 cells (transfected
with various plasmid DNAs such as HA-tagged C1199 Tiam1cDNA,
GFP-tagged PHn-CC-ExcDNA, or HA-tagged C1199Tiam1cDNA plus
GFP-tagged PHn-CC-ExcDNA (as co-transfection) or vector alone) were
first washed with PBS buffer (0.1 M phosphate buffer (pH
7.5) and 150 mM NaCl) and fixed by 2% paraformaldehyde. Subsequently, SP1 transfectants were stained with rhodamine
(Rh)-labeled rabbit anti-CD44v3 antibody. In some cases, Rh-labeled
cells were then rendered permeable by ethanol treatment followed by
incubating with FITC-conjugated mouse anti-HA IgG. To detect
nonspecific antibody binding, Rh-CD44v3-labeled cells were incubated
with FITC-conjugated normal mouse IgG. No labeling was observed in such
control samples. The fluorescein- and rhodamine-labeled samples were
examined with a confocal laser scanning microscope (MultiProbe 2001 Inverted CLSM system, Molecular Dynamics, Sunnyvale, CA).
Cell Adhesion Assay--
SP1 cells were metabolically labeled
with Tran35S label (20 µCi/ml) as described above. After
labeling, the cells were washed in PBS and incubated in PBS containing
5 mM EDTA at 37 °C to obtain a nonadherent single cell
suspension. Labeled cells (
9.1 × 105
cpm/105 cells) (in the presence or absence of anti-CD44v3
antibody) were plated on the HA-coated plates at 4 °C for 30 min.
Following incubation, the wells were washed three times in PBS, the
adherent cells were solubilized in PBS containing 1% SDS, and the well
bound radioactivity was determined by liquid scintillation counting.
Nonspecific binding was determined by including 300 µg/ml soluble HA
during the incubation of cells on HA-coated wells. The nonspecific
binding was 10-15% of the total well-associated radioactivity and has
been subtracted.
Tumor Cell Migration Assays--
Twenty-four transwell units
were used for monitoring in vitro cell migration as
described previously (23). Specifically, the 5-µm porosity
polycarbonate filters (CoStar Corp., Cambridge, MA) were used for the
cell migration assay. SP1 cells (
1 × 104
cells/well in PBS, pH 7.2) (in the presence or absence of anti-CD44v3 antibody (50 µg/ml)) were placed in the upper chamber of the
transwell unit. In some cases, cells were transfected with either
C1199Tiam1cDNA, PHn-CC-ExcDNA, C1199Tiam1cDNA plus
PHn-CC-ExcDNA, or vector alone. The growth medium containing high
glucose Dulbecco's modified Eagle's medium supplemented with 200 µg/ml hyaluronic acid was placed in the lower chamber of the
transwell unit. After 18 h of incubation at 37 °C in a
humidified 95% air/5% CO2 atmosphere, the 3-(4,5-dimethyl
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Promega) was added at a
final concentration of 0.2 mg/ml to both the upper and the lower
chambers and incubated for an additional 4 h at 37 °C.
Migrative cells at the lower part of the filter were removed by
swabbing with small pieces of Whatman filter paper. Both the
polycarbonate filter and the Whatman paper were placed in dimethyl
sulfoxide to solubilize the crystal. Color intensity was measured in
450 nm. Cell migration processes were determined by measuring the cells
that migrate to the lower side of the polycarbonate filters by standard
cell number counting methods as described previously (23, 49). The
CD44-specific cell migration was determined by subtracting nonspecific
cell migration (i.e. cells migrate to the lower chamber in
the presence of anti-CD44v3 antibody treatment) from the total
migrative cells in the lower chamber. The CD44-specific cell migration
in vector-transfected cells (control) is designated as 100%. Each
assay was set up in triplicate and repeated at least three times. All
data were analyzed statistically using the Student's t
test, and statistical significance was set at p < 0.01.
 |
RESULTS |
Identification of CD44 Variant Isoform(s) as HA Receptor(s) in SP1
Cells--
The expression of CD44 variant isoforms such as CD44v3 is
known to be closely correlated with metastatic and proliferative behavior of a variety of tumor cells including various carcinomas such
as human breast tumor cells (14-19). Immunoblotting with anti-CD44v3 antibody (recognizing the v3-specific sequence located at the membrane-proximal region of the extracellular domain of CD44) indicates
that a single CD44v3 protein (molecular mass = ~260 kDa) is
expressed in SP1 cells (Fig. 1,
lane 1). Furthermore, we have utilized surface biotinylation
techniques and anti-CD44v3-mediated immunoprecipitation to characterize
this CD44v3 molecule. Our results show that the 260-kDa CD44v3 molecule
can be surface-biotinylated and is located on the surface of SP1 cells
(Fig. 1, lane 3). No CD44v3-containing material
is observed in control samples when preimmune rabbit serum is used in
either immunoblot (Fig. 1, lane 2) or immunoprecipitation
experiments (Fig. 1, lane 4). Further analyses using reverse
transcriptase-PCR, cloning, and nucleotide sequence techniques indicate
that this CD44v3 belongs to the CD44v3,8-10 isoform in SP1
cells (data not shown). This CD44v3,8-10 variant exon
structure was previously identified in human breast carcinoma samples
(14-19), and its molecular mass (expressed at the protein level) has
been shown to be
260 kDa (9).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of CD44v3 in breast tumor
cells. Breast tumor cells (SP1 cell line) were surface
biotinylated (or unlabeled) and solubilized in a buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 1%
Triton X-100. The solubilized materials were then immunobloted or
immunoprecipitated by anti-CD44v3 antibody as described under
"Materials and Methods." Lane 1, immunoblot of unlabeled
SP1 cell lysate using rabbit anti-CD44v3 antibody; lane 2,
immunoblot of unlabeled SP1 cells with preimmune rabbit serum;
lane 3, immunoprecipitation of surface biotinylated SP1
cells using rabbit anti-CD44v3 antibody; lane 4,
immunoprecipitation of surface biotinylated SP1 cells with preimmune
rabbit serum.
|
|
CD44 is the major hyaluronan cell surface receptor (50), and a cellular
adhesion molecule in many different cell types (51). Specific
HA-binding motifs have been identified and localized in the
extracellular domain of all CD44 isoforms (52, 53). To determine
whether HA promotes cell adhesion, breast tumor cells (SP1 cell line)
were incubated with plastic dishes coated with HA. As shown in Table
I, SP1 cells adhere to the HA-coated
dishes very well. In addition, because preincubation with anti-CD44v3 antibody blocks the adhesion of SP1 cells to HA-coated dishes, these
data clearly indicate that CD44v3 isoform involves a specific binding
interaction with the extracellular matrix component such as HA and is a
cell surface adhesion molecule in SP1 cells.
View this table:
[in this window]
[in a new window]
|
Table I
CD44v3-mediated adhesion of metabolically labeled SP1 cells
to HA-coated plates
Trans35S-labeled SP1 cells were pretreated with or without
anti-CD44v3 antibody treatment. Subsequently, these cells were
incubated in tissue culture wells coated with HA as described under
"Materials and Methods." The background level of binding was
determined by cell adhesion performed in the presence of an excess
amount of soluble HA. The results were expressed in terms of
HA-specific binding in which the background levels of binding have been
subtracted. Data are expressed as mean cpm ± S.E. of triplicate
determinations.
|
|
Analysis of a Complex Formed between CD44v3 and Tiam1 in SP1 Cells
in Vivo--
Both CD44v isoforms (14-19) and Tiam1 (39) have been
detected in a variety of tumor cells. In this study we have addressed the question of whether there is an interaction between CD44v3 isoform
and Tiam1 in breast tumor cells (e.g. SP1 cells). First, we
have analyzed Tiam1 expression (at the protein level) in breast tumor
cells such as SP-1 cell line. Immunoblot analysis, utilizing anti-Tiam1
antibody designed to recognize the specific epitope located at the
COOH-terminal sequence of Tiam1 reveals a single polypeptide (molecular
mass = ~200 kDa) (Fig. 2,
lane 2). We have demonstrated that Tiam1 detected in SP1
cells revealed by anti-Tiam1-mediated immunoblot is specific because no
protein is detected in these cells using preimmune rabbit IgG (Fig. 2,
lane 1). Furthermore, we have carried out
anti-CD44v3-mediated and anti-Tiam1-mediated precipitation followed by
anti-Tiam1 immunoblot (Fig. 2, lane 3) or anti-anti-CD44v3
immunoblot (Fig. 2, lane 4), respectively, using
SDS-polyacrylamide gel electrophoresis analyses. Our results clearly
indicate that the Tiam1 band is revealed in
anti-CD44v3-immunoprecipitated materials (Fig. 2, lane 3).
The CD44v3 band can also be detected in the
anti-Tiam1-immunoprecipitated materials (Fig. 2, lane 4). These findings clearly establish the fact that CD44v3 and Tiam1 are
closely associated with each other in vivo in breast tumor cells.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Detection of Tiam1 and Tiam1-CD44v3 complex
in SP1 cells. SP1 cells (5 × 105 cells) were
solubilized by 1% Nonidet P-40 buffer followed by immunoprecipitation
and/or immunblot by anti-Tiam1 antibody or anti-CD44v3 antibody,
respectively, as described under "Materials and Methods."
Lane 1, immunoblot of SP1 cells with preimmune rabbit serum;
lane 2, detection of Tiam1 with anti-Tiam1-mediated
immunoblot of SP1 cells; lane 3, detection of Tiam1 in the
complex by anti-CD44v3-immunoprecipitation followed by immunoblotting
with anti-Tiam1 antibody; lane 4, detection of CD44v3 in the
complex by anti-Tiam1 immunoprecipitation followed by immunoblotting
with anti-CD44v3 antibody.
|
|
In Vitro Binding Between Tiam1 (or PHn-CC-Ex Domain) and
CD44--
Previous studies indicate that Tiam1 membrane localization
(through its NH2-terminal PHn domain and an adjacent
protein interaction domain (designated as PHn-CC-Ex, a sequence between
amino acids 393-738 of Tiam1)) (Fig. 3,
A and C) is required for the activation of Rac1
signaling pathways leading to membrane ruffling and c-Jun NH2-terminal kinase activation (37, 54). To test whether
CD44 is one of the membrane proteins involved in the direct binding to
Tiam1, we have used purified CBP-tagged PHn-CC-Ex fusion protein (Figs.
3C and 4, lane 1)
and the FLAG-tagged cytoplasmic domain of CD44 (FLAG-CD44cyt) fusion
protein (Fig. 4, lane 2) to identify the CD44 binding site
on the Tiam1 molecule. Specifically, we have tested the binding of
FLAG-CD44cyt to 125I-labeled CBP-PHn-CC-EX (or
125I-labeled intact Tiam1) under equilibrium binding
conditions. Scatchard plot analyses presented in Fig.
5 indicate that PHn-CC-Ex binds to the
cytoplasmic domain of CD44 (CD44cyt) at a single site (Fig.
5A) with high affinity (an apparent dissociation constant (Kd) of
0.2 nM). This interaction
between PHn-CC-Ex and CD44 is comparable in affinity with CD44 binding
(Kd = ~0.13 nM) to intact Tiam1 (Fig.
5B). These findings clearly indicate that Tiam1 (in
particular, PHn-CC-Ex domain) contains the CD44 binding site.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Illustration of Tiam1 full-length
(A) and deletion mutant cDNA constructs
(B and C). The full-length Tiam1
contains a Dbl homology domain (DH), a Discs large homology
region (DHR), two pleckstrin homology (PH)
domains (including the NH2-terminal PH (PHn) and
the COOH-terminal PH (PHc)), a putative coiled coil region
(CC), and an additional adjacent region (Ex). The
NH2-terminally truncated C1199 Tiam1 encodes the
COOH-terminal 1199 amino acids (B). PHn-CC-Ex domain of
Tiam1 encodes the sequence between amino acids 393 and 738 (C).
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Characterization of various recombinant
proteins used in the in vitro binding assay.
Lane 1, a Coomassie Blue staining of CBP-PH-CC-Ex fusion
protein purified by calmodulin affinity resin column chromatography;
lane 2, a Coomassie Blue staining of FLAG-CD44cyt fusion
protein eluted from affinity column chromatography with FLAG
peptide.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Binding of 125I-labeled PHn-CC-Ex
(or Tiam1) to FLAG-CD44cyt. Various concentrations of
125I-labeled PHn-CC-Ex (or Tiam1) were incubated with
FLAG-CD44cyt-coupled beads at 4 °C for 4 h. Nonspecific binding
was determined in the presence of 50-fold excess of unlabeled PHn-CC-Ex
(or Tiam1) and subtracted from the total binding. Results represent an
average of duplicate determinations from the same experiment. Data
presented are the representative of three individual binding
experiments. A, Scatchard plot analysis of the equilibrium
binding data between 125I-labeled PHn-CC-Ex and
FLAG-CD44cyt. B, Scatchard plot analysis of the equilibrium
binding data between 125I-labeled intact Tiam1 and
FLAG-CD44cyt.
|
|
Further analyses using an in vitro binding assay show that
surface biotinylated CD44v3 (isolated from SP1) specifically binds to
Tiam1 (including intact Tiam1 (Fig. 6,
lane 1), HA-tagged C1199 Tiam1 (Fig. 6, lane 2)
or Tiam1 fragment (PHn-CC-Ex) (Fig. 6, lane 3))-coated
beads. In the presence of an excess amount (
100-fold) of recombinant
PHn-CC-Ex Tiam1 fragment, the binding interaction between CD44v3 and
theseTiam1-related proteins is readily abolished (Fig. 6, lanes
4-6). These observations suggest that (i) the breast tumor
cell-specific CD44v3 is also capable of interacting with Tiam1
(e.g. intact Tiam1 (Fig. 6, lane 1), HA-tagged
C1199 Tiam1 (Fig. 6, lane 2), or Tiam1 fragment (PHn-CC-Ex)
(Fig. 6, lane 3)); and (ii) the Tiam1 fragment such as
PHn-CC-Ex acts as a potent competitive inhibitor for Tiam1 binding to
CD44v3 in vitro (Fig. 6, lanes 4-6).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
In vitro binding between CD44v3
and Tiam1-related protein. CD44v3 was immunoprecipitated from
surface biotinylated SP1 cells by anti-CD44v3 antibody as described
under "Materials and Methods." Subsequently, purified surface
biotinylated CD44v3 was incubated with Tiam1, C1199 Taim1, or
PHn-CC-Ex-coated beads in the binding buffer (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% bovine serum albumin,
and 0.05% Triton X-100) at room temperature for 1 h. After
extensive washing, protein bound on the beads were eluted and analyzed
with Extravidin (horseradish peroxidase-conjugated). Lane 1,
binding of CD44v3 to Tiam1-conjugated beads; lane 2, binding
of CD44v3 to C1199 Tiam1-conjugated beads; lane 3, binding
of CD44v3 to PHn-CC-Ex-conjugated beads; lane 4, binding of
CD44v3 to Tiam1-conjugated beads in the presence of an excess amount
( 100-fold) of soluble PHn-CC-Ex; lane 5, binding of
CD44v3 to C1199 Tiam1-conjugated beads in the presence of an excess
amount ( 100-fold) of soluble PHn-CC-Ex; lane 6, binding
of CD44v3 to PHn-CC-Ex-conjugated beads in the presence of an excess
amount ( 100-fold) of soluble PHn-CC-Ex.
|
|
Tiam1-catalyzed Rac1 Activation in SP1 Cells--
Rac1
GTPase becomes activated when bound GDP is exchanged for GTP by a
process catalyzed by guanine nucleotide (GDP-GTP) exchange factors or
GDP dissociation stimulator proteins (i.e. promoting GTP
binding to RhoA by facilitating the release of GDP) (25, 26). Tiam1 is
known to function as an exchange factor for the Rho-like GTPases such
as Rac1 (34, 40-42). To investigate whether Tiam1 complexed with
CD44v3 acts as a GDP/GTP exchange factor (or a GDP dissociation
stimulator protein) for E. coli-derived GST-Rac1, we have
isolated Tiam1 complexed with CD44v3 from SP1 cells using
anti-Tiam1-conjugated Sepharose beads. Our data show that Tiam1
complexed with CD44v3 from SP1 cells causes the exchange of preloaded
GDP for [35S]GTP
S on GST-Rac1 in a
time-dependent manner (Fig.
7, lines a and b).
Most importantly, addition of HA to CD44v3 containing SP1
cells stimulates the total amount of bound [35S]GTP
S
to GST-Rac1 (Fig. 7, line b) (at least 1.5-fold increase) as
compared with Tiam1 isolated from untreated SP1 cells (Fig. 7,
line b) or HA-treated SP1 cells in the presence of
anti-CD44v3 antibody (data not shown). No
[35S]GTP
S-bound material was detected in these samples
containing GST alone under the same GDP/GTP exchange reaction using
Tiam1 isolated from SP1 cells (in the presence (Fig. 7, line
c) or absence (Fig. 7, line d) of HA treatment). These
findings suggest that the HA interaction with CD44v3
isoform-containing SP1 cells promotes Tiam1 activation of Rac1.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Tiam1-mediated GDP/GTP exchange for Rac1
protein. Tiam1 isolated from SP1 cells (treated with HA or without
any treatment) was preincubated for 10 min with 0.25 µM
[35S]GTP S (1,250 Ci/mmol) and 2.25 µM
GTP S (or in the presence of 1 mM unlabeled GTP S)
followed by adding GDP-loaded GST-Rac1 GTPases (or GST alone). The
amount of [35S]GTP S bound to samples in the absence of
GTPases was subtracted from the original values. Data represent an
average of triplicates from three to five experiments. The standard
deviation was less than 5%. Line a, kinetics of
[35S]GTP S bound to GDP-loaded GST-Rac1 in the presence
of Tiam1 (isolated from SP1 cells treated with HA); line b,
kinetics of GTP 35S bound to GDP-loaded GST-Rac1 in the
presence of Tiam1 (isolated from SP1 cells without any treatment);
line c, kinetics of [35S]GTP S bound to
GDP-treated GST in the presence of Tiam1 (isolated from SP1 cells
treated with HA); line d, kinetics of
[35S]GTP S bound to GDP treated GST in the presence of
Tiam1 (isolated from SP1 cells without any treatment).
|
|
CD44v3-Tiam1 Interaction in Rac1 Signaling and
Cytoskeleton-mediated Tumor Cell Migration--
Previous studies
indicate that the invasive phenotype of tumor cells characterized by an
invadopodia structure (or membranous projections) (56, 57) and tumor
cell migration (28, 29) is closely associated with
CD44v3,8-10-linked cytoskeleton function (23). In this
study we have transiently transfected breast tumor cells
(e.g. SP-1 cells) with HA-tagged NH2-terminally truncated C1199 Tiam1 cDNA (Fig. 3B). Our results show
that the C1199 Tiam1 is expressed as a 150-kDa protein (Fig.
8A, lane 1) detected by anti-HA-mediated immunoblot in CD44v3-positive
breast tumor cells (SP1 cells). No protein band was detected in
vector-transfected SP1 cells by anti-HA-mediated immunoblotting (Fig.
8A, lane 3). Using anti-CD44v3
immunoprecipitation of SP1 cellular protein followed by immunoblotting
with anti-HA antibody, we have found that the 150-kDa C1199 Tiam1 is
co-precipitated with CD44v3 (Fig. 8A, lane 2). In
control samples, immunoblotting of rabbit preimmune IgG-precipitated
material using anti-HA antibody does not reveal any protein associated
with this material (Fig. 8A, lane 4). Double immunofluorescence staining data also confirms the close association between CD44v3 (Fig. 9A) and
the C1199 Taim1 (Fig. 9B) in the plasma membranes and long
membrane projections. In contrast, vector-transfected cells expressing
CD44v3 on the surface (Fig. 9, inset a) (with no detectable
C1199 Tiam1 by anti-HA label (Fig. 9, inset b)) fail to
display long membrane projections. Furthermore, we have demonstrated
that transfection of SP1 cells with C1199 Tiam1 cDNA stimulates
CD44v3-associated Tiam1-catalyzed GDP/GTP exchange on Rac1 (Table
II) and induces a significant amount of
increase in CD44v3-specific and HA-mediated breast tumor cell migration (Table II) compared with vector-transfected SP1 transfectants (Table
II). These results are consistent with previous findings indicating
that transfection of NIH3T3 cells with the NH2-terminally truncated C1199 Tiam1 cDNA confers potent oncogenic properties (42). Treatment of SP1 cells (e.g. untransfected cells or
transfected cells) with certain agents (e.g. cytochalasin D
(a microfilament inhibitor)) causes a remarkable inhibition of
CD44v3/HA-specific tumor cell migration (Table II). These observations
suggest that CD44v3-associated Tiam1 signaling and
cytoskeleton-mediated tumor cell motility are closely coupled.

View larger version (80K):
[in this window]
[in a new window]
|
Fig. 8.
Transfection of SP1cells with HA-tagged
C1199Tiam1cDNA (A) or GFP-tagged PHn-CC-ExcDNA
(B) or co-transfection of HA-tagged C1199Tiam1cDNA
and GFP-tagged PHn-CC-ExcDNA (C).
A, detection of C1199 Tiam1 expression by anti-HA-mediated
immunoblot in HA-tagged C1199 Tiam1cDNA transfected cells
(lane 1) or in vector-transfected cells (lane 3);
immunoblot of anti-CD44v3 immunoprecipitated materials (lane
2) or rabbit preimmune IgG precipitated materials (lane
4) from HA-tagged C1199 Tiam1cDNA transfected cells with
anti-HA antibody. B, detection of PHn-CC-Ex expression by
anti-GFP-mediated immunoblot in GFP-tagged PHn-CC-Ex cDNA
transfected cells (lane 1) or vector-transfected cells
(lane 3); immunoblot of anti-CD44v3 immunoprecipitated
materials (lane 2) or rabbit preimmune IgG precipitated
materials (lane 4) from GFP-tagged PHn-CC-Ex cDNA
transfected cells with anti-GFP antibody. C, detection of
co-expression of C1199 Tiam1 and PHn-CC-Ex by immunoblotting of cells
(co-transfected with HA-tagged C1199 Tiam1cDNA and GFP-tagged
PHn-CC-Ex cDNA) with anti-HA antibody (row a, lane
1) and anti-GFP antibody (row b, lane 1),
respectively; immunoblotting of vector-transfected cell lysate with
anti-HA antibody (row a, lane 3) and anti-GFP
antibody (row b, lane 3), respectively;
immunoblot of anti-CD44v3 immunoprecipitated materials (from HA-tagged
C1199 Tiam1cDNA and GFP-tagged PHn-CC-Ex cDNA co-transfected
cells) using anti-HA antibody (row a, lane 2) and
anti-GFP antibody (row b, lane 2), respectively.
Immunoblot of rabbit preimmune IgG-precipitated materials (from
HA-tagged C1199 Tiam1cDNA and GFP-tagged PHn-CC-Ex cDNA
co-transfected cells) using anti-HA antibody (row a,
lane 4) and anti-GFP antibody (row b, lane
4), respectively.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 9.
Double immunofluorescence staining of CD44v3
and Tiam1 cDNA (e.g. C1199 Tiam1 cDNA or
PHn-CC-Ex cDNA)-transfected SP1 cells. SP1 cells (transfected
with HA-tagged C1199 Tiam1 cDNA or GFP-tagged PHn-CC-Ex cDNA or
co-transfected with HA-tagged C1199 Tiam1 cDNA plus GFP-tagged
PHn-CC-Ex cDNA) were fixed by 2% paraformaldehyde. Subsequently,
cells were surface labeled with Rh-labeled rabbit anti-CD44v3 antibody.
Some cells were then rendered permeable by ethanol treatment and
stained with FITC-labeled mouse anti-HA IgG. A and
B, Rh-labeled anti-CD44v3 staining (A) and
FITC-anti-HA-labeled C1199 Tiam1 staining (B) in HA-tagged
C1199 Tiam1 cDNA transfected SP1 cells. Insets a and
b, Rh-labeled anti-CD44v3 staining (a) and
FITC-anti-HA staining (b) in vector-transfected SP1 cells.
C and D, Rh-labeled anti-CD44v3 staining
(C) and GFP-tagged PHn-CC-Ex domain (D) in
GFP-tagged PHn-CC-Ex cDNA transfected SP1 cells. Insets
c and d, Rh-labeled preimmune IgG staining
(c) and GFP-tagged PHn-CC-Ex domain (d) in
GFP-tagged PHn-CC-Ex cDNA transfected SP1 cells. E and
F, Rh-labeled anti-HA staining of C1199 Tiam1 (E)
and GFP-tagged PHn-CC-Ex domain (F) in SP1 cells
co-transfected with HA-tagged C1199 cDNA and GFP-tagged PHn-CC-Ex
cDNA. Insets e and f, Rh-labeled anti-CD44v3
staining (e) and GFP-tagged PHn-CC-Ex domain (f)
in SP1 cells co-transfected with HA-tagged C1199 cDNA and
GFP-tagged PHn-CC-Ex cDNA.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Measurement of CD44v3-associated Tiam1-catalyzed Rac1
activation and HA-mediated/cytoskeleton-mediated breast tumor cell
migration
|
|
Moreover, we have found that SP1 cells transfected with GFP-tagged
PHn-CC-Ex Tiam1 cDNA express a 68-kDa protein as detected by
anti-GFP antibody (Fig. 8B, lane 1). In
vector-transfected SP1 cells, we are not able to detect any protein
band by anti-GFP-mediated immunoblotting (Fig. 8B,
lane 3). Using anti-CD44v3 immunoprecipitation of SP1
cellular protein followed by immunoblotting with anti-GFP antibody, we
have found that the 68-kDa PHn-CC-Ex Tiam1 fragment is co-precipitated
with CD44v3 (Fig. 8B, lane 2). No protein band was found when immunoblotting of rabbit preimmune IgG-precipitated materials with anti-GFP antibody was used (Fig. 8B,
lane 4). It is also noted that both GFP-tagged PHn-CC-Ex
domain (Fig. 9D) and CD44v3 are co-localized in the plasma
membranes (Fig. 9C). However, no significant stimulation of
long membrane projection was observed in these cells (Fig. 9,
C, D, and insets c and d). Furthermore, we have demonstrated that CD44v3 staining detected in
these SP1 transfectants revealed by anti-CD44v3-mediated immunostaining is specific because no surface label (Fig. 9, inset c) is
detected in these GFP-PHn-CC-Ex overexpressed cells (Fig. 9,
inset d) using preimmune rabbit IgG (Fig. 9, inset
c). Additionally, we have demonstrated that overexpression of
GFP-tagged PHn-CC-Ex domain in SP1 transfectants does not cause any
significant changes of breast tumor cell properties (e.g.
CD44v3-associated Tiam1-Rac1 signaling or HA-mediated tumor cell
migration (Table II))
Finally, we have conducted co-transfection of SP1 cells with HA tagged
C1199 Tiam1 cDNA and GFP-tagged PHn-CC-Ex cDNA. Our results
indicate that C1199 Tiam1 and PHn-CC-Ex Tiam1 fragment are co-expressed
as a 150-kDa protein (Fig. 8C, row a, lane
1) and a 68-kDa protein (Fig. 8C, row b,
lane 1), respectively, in SP1 cells. No protein band was
revealed in vector-transfected SP1 cells by anti-HA (Fig.
8C, row a, lane 3) or
anti-GFP-mediated (Fig. 8C, row b, lane
3) immunoblotting. Using anti-C44v3 antibody immunoprecipitation
of SP1 cell lysate followed by immunoblotting with anti-GFP antibody
and anti-HA, respectively, we have found that the 68-kDa PHn-CC-Ex
Tiam1 fragment (Fig. 8C, row b, lane 2) (but not 150-kDa C1199 Tiam1 (Fig. 8C, row
a, lane 2)) is co-precipitated with CD44v3. In control
samples, immunoblotting of rabbit preimmune IgG-precipitated material
using anti-HA antibody (Fig. 8C, row a,
lane 4) or anti-GFP antibody (Fig. 8C, row
b, lane 4) does not reveal any protein associated with
this material. Immunocytochemical staining results confirm that the
PHn-CC-Ex Tiam1 fragment (Fig. 9, inset e) is co-localized
with CD44v3 (Fig. 9, inset f) in the plasma membranes of SP1
transfectants. In contrast, the C1199 Tiam1 (Fig. 9E) fails
to display plasma membrane localization as the PHn-CC-Ex domain does
(Fig. 9F). Co-expression of PHn-CC-Ex domain and C1199 Tiam1
also efficiently blocks CD44v3-associated Tiam1-Rac1 activation and
CD44v3-dependent and HA-mediated breast tumor cell
migration (Table II). These results are consistent with a previous
report showing that co-transfection of COS-7 cells with PHn-CC-Ex
cDNA and C1199 Tiam1 cDNA results in an inhibition of C1199
Tiam1-induced Rac1 signaling and membrane ruffling (54). These findings
suggest that the NH2-terminal PHn domain and an adjacent
protein interaction domain (PHn-CC-Ex) play an important role in
regulating Tiam1 localization to the plasma membrane proteins such as
CD44v3 isoforms and for oncogenic signaling during extracellular matrix
component (e.g. hyaluronic acid)-regulated breast tumor cell
invasion and migration.
 |
DISCUSSION |
CD44 denotes a family of glycoproteins (e.g. CD44s
(standard form), CD44E (epithelial form), and CD44v (variant isoforms)) that are expressed in a variety of cells and tissues (1-6). Clinical studies indicate that a number of CD44v isoforms have been detected at
high levels on the surface of tumor cells during tumorigenesis and
metastasis (13-17). As the histologic grade of each of the tumors
progresses, the percentage of lesions expressing an associated CD44v
isoform increases. In particular, the CD44v3-containing isoforms are
detected preferentially on highly malignant breast carcinoma
tissue samples. In fact, there is a direct correlation between CD44v3
isoform expression and increased histologic grade of the malignancy
(14, 17, 57).
It has been speculated that some of these CD44v3 isoforms on epithelial
cells may act as surface modulators to facilitate unwanted growth
factor receptor-growth factor interactions (9, 10) and subsequent tumor
formation. The CD44-related glycoproteins are also known to mediate
cell adhesion to extracellular matrix components (e.g. HA)
and to function as the major hyaluronate receptor (50). In this study
we have demonstrated that a 260-kDa CD44v3 isoform is expressed on the
surface of breast tumor cells (SP1 cell line) (Fig. 1) and that it
interacts with extracellular matrix HA as an adhesion receptor (Table
I). Furthermore, addition of HA to SP1 cells stimulates tumor cell
migration in a CD44v3-specific and cytoskeleton-dependent
manner (Table II). These findings are consistent with previous findings
that CD44v isoforms expressed in tumor cells often display enhanced
hyaluronic acid binding, which increases cell migration capability (58,
59).
The invasive phenotype of CD44v3-mediated breast tumor cells,
characterized by invadopodia formation (23), matrix metalloproteinase-9 activation (23, 24), and tumor cell motility (23, 48) has been linked
to cytoskeletal function, a process in which the small GTP-binding
proteins such as RhoA and Rac1 are shown to play important roles.
Tsukita and co-workers (60) have reported that Rho-like proteins
participate in the interaction between the CD44 and the ERM
cytoskeletal proteins. Our recent study determined that RhoA is
physically linked to CD44v3 isoform (e.g. CD44v3,
8-10) in breast tumor cells (48). Rho-kinase stimulated by
activated RhoA (GTP-bound form of RhoA) appears to play a pivotal role
in promoting CD44v3,8-10-ankyrin interaction during
membrane-cytoskeleton function and metastatic breast tumor cell
migration (48). Signaling to the RacGTPase known to regulate actin
assembly associated with membrane ruffling, pseudopod extension, cell
motility, and cell transformation (33-37) has been shown to be
abnormal in breast tumor cells as compared with normal breast
epithelial cells (61). The fact that Rac1 induces stress fiber
formation in a Rho-dependent manner suggests that
cross-talk occurs between the Rho and Rac1 signaling pathways (33). The
question of whether the activation of Rac1 signaling is involved in
CD44v3-cytoskeleton-mediated breast tumor-specific events remains to be answered.
Tiam1, which was identified by retroviral insertional mutagenesis and
selected for its invasive cell behavior in vitro, has been
shown to regulate Rac1 activation (38, 39). This molecule is largely
hydrophilic and contains several functional domains including a Dbl
homology domain (38, 62, 63), a Discs large homology region (38, 64),
and two pleckstrin homology (PH) domains (e.g. PHn (the PH
domain located at the NH2-terminal region of the molecule;
and PHc (the PH domain located at the COOH-terminal region of the
molecule)) (Fig. 3) (38). In particular, the Dbl homology domain of
Tiam1 exhibits GDP/GTP exchange activity for specific members of the
Ras superfamily of GTP-binding proteins (62, 63) and plays an important
role in Rac1 signaling and cellular transformation (33-37). In breast
tumor cells (e.g. SP1 cells), Tiam1 is detected as a 200-kDa
protein (Fig. 2) that is capable of carrying out GDP/GTP exchange for
Rac1 (Fig. 7), similar to Tiam1 described in other cell types (34,
40-42, 65, 66). Other functional domains such as Discs large homology
region have been implicated in the binding of membrane protein networks
(38, 64). The PH domain may mediate association with the submembrane region of the cell via protein-protein or protein-lipid interactions (67). Based on mutational analyses and immunofluorescence staining, Collard and co-workers (37, 54) report that the
NH2-terminal PHn domain (but not PHc) and an adjacent
protein interaction domain (e.g. PHn-CC-Ex domain) (Fig. 3)
are required for Tiam1 targeting to the plasma membrane and Rac1
activation in fibroblasts. At the present time, identification of the
membrane protein(s) involved in Tiam1 binding has not been established.
In this study we have presented new evidence that a close interaction
occurs between Tiam1 and certain plasma membrane proteins such as
CD44v3 isoform. Using two recombinant proteins (CBP-tagged PHn-CC-Ex
domain (Fig. 4, lane 1) and FLAG-tagged CD44 cytoplasmic domain (FLAG-CD44cyt) (Fig. 4, lane 2)), we have
demonstrated that the PHn-CC-Ex domain of Tiam1 is directly involved in
the binding to the cytoplasmic domain of CD44 (Figs. 5 and 6). In fact,
the binding affinity of the PHn-CC-Ex domain of Tiam1 to CD44 is
comparable with the intact Tiam1 binding to CD44 (Figs. 5 and 6). In
the presence of PHn-CC-Ex, the binding between Tiam1 and CD44
(e.g. CD44v3) is greatly reduced (Fig. 6). The ability of
PHn-CC-Ex to effectively compete for Tiam1 binding to the plasma membrane proteins such as CD44v3 (Fig. 6) strongly suggests that the
PHn-CC-Ex of Tiam1 is responsible for the recognition of CD44 in
vitro.
In addition, we have detected that Taim1 and CD44v3 are physically
linked to each other as a complex in vivo (Figs. 2, 8, and
9) and that HA binding to CD44v3 promotes Tiam1-catalyzed Rac1
activation (Fig. 7 and Table II) and tumor cell migration (Table II).
Our data also indicate that overexpression of Tiam1 (by transfecting
SP1 cells with C1199 Tiam1cDNA) (Figs. 8 and 9) not only promotes
C1199 Tiam1 association with CD44v3 (Figs. 8 and 9) but also enhances
the metastatic capability of tumor cells (e.g. Rac1
activation and tumor cell migration (Table II)). These results suggest
that Tiam1 and CD44v3 are not only structurally linked but also
functionally coupled. Previously, it has been shown that
Tiam1-activated Rac1 initiates oncogenic signaling cascades that
involve activation of c-Jun NH2-terminal kinase (37, 54)
and a novel family of serine/threonine kinases, Paks (p-21 activated
kinases) (68, 69). However, the identification of CD44v3-Tiam1-mediated
downstream targets (e.g. c-Jun NH2-terminal kinase and/or Paks activities) during HA-mediated breast tumor progression and metastasis remains to be answered.
Furthermore, we have found that co-transfection of SP1 cells with
PHn-CC-Ex cDNA and C1199 Tiam1cDNA (Figs. 8 and 9) effectively blocks tumor cell-specific behaviors (e.g. C1199 Tiam1
association with CD44v3 (Figs. 8 and 9), Rac1 signaling (Table II), and
tumor cell migration (Table II)). These findings further support our conclusion that PHn-CC-Ex acts as a potent competitive inhibitor that
is capable of interfering with C1199 Tiam1-CD44v3 interaction in
vivo. Recently, we have also identified a unique sequence residing within the PHn-CC-Ex domain as the putative cytoskeletal binding site
of Tiam1 (70). Most importantly, interaction between Tiam1 and the
cytoskeleton up-regulates the GDP/GTP exchange activity of Rho-like
GTPases and stimulates breast tumor cell invasion/migration (70). These
observations clearly suggest that the PHn-CC-Ex fragment of Tiam1 is
one of the important regulatory domains required for Tiam1 function.
In fibroblasts, Tiam1-induced membrane ruffling is dependent on Rac1
(but not RhoA) activity (71). The fact that Tiam1 is involved in both
Rac1- and RhoA-mediated pathways during neurite formation in nerve
cells suggests that the balance between two Tiam1-activated Rho-like
GTPases (e.g. Rac1 and RhoA) determines a particular
biological activity (65). Tiam1-Rac1 signaling is also implicated in
promoting integrin-mediated cell-cell and cell-extracellular matrix
interaction and lymphoid cell invasion (34, 65). In addition, the
laminin receptor,
6
1 integrin appears to
require Rac1 as a downstream of Tiam1 signaling in neuroblastoma cell
activation (65). In epithelial Madin-Darby canine kidney cells,
fibronectin and/or laminin1-induced Tiam1-Rac1 signaling up-regulates
E-cadherin-mediated adhesion and plays an invasion-suppressor role in
Ras-transformed Madin-Darby canine kidney cells (66). However, if
Madin-Darby canine kidney cells were grown on different collagen
substrates, the expression of Tiam1 or constitutively activated Rac1
(V12Rac) in these cells is able to inhibit the appearance of E-cadherin
adhesion and promote cell migration (72, 73). Our studies show that
approximately 60% (63 ± 4%, n = 5) of the GDP
dissociation activity can be detected in the guanine nucleotide
exchange assay using Tiam1 isolated from untreated breast tumor cells
(Fig. 7 and Table II). We have also observed that approximately 90%
(92 ± 5%, n = 5) of Rac1 is exchanging GDP for
GTP in the presence of Tiam1 isolated from either HA-treated cells
(Fig. 7) or C1199 Tiam1 cDNA-transfected breast tumor cells (Table
II). These findings suggest that Tiam1-catalyzed Rac1 activation is
tightly regulated by various signals. Apparently, different responses
by Tiam1-catalyzed Rho-like GTPases are controlled by specific upstream
activators (in particular, cell adhesion receptors (e.g.
CD44, integrin, or E-cadherin, etc.) or extracellular matrix components
(e.g. HA, collagens, laminin, or fibronectin, etc.)), which
may result in selective Tiam1-activated Rho-like GTPases and
distinct biological outcome. In summary, we believe that Tiam1-CD44v3
interaction plays a pivotal role in regulating oncogenic signaling
required for RhoGTPase activation and cytoskeleton function during
HA-mediated metastatic breast tumor cell progression. This could be one
of the critical steps in CD44 variant isoform-mediated breast tumor
spread and metastasis.
 |
ACKNOWLEDGEMENTS |
We gratefully acknowledge Dr. Gerard J. Bourguignon's assistance in the preparation of this paper. We also
thank Dr. Dan Zhu for help in reviewing the manuscript.
 |
FOOTNOTES |
*
This work was supported by United States Public Health
Grants CA66163 and CA 78633 and Department of Defense Grants DAMD
17-94-J-4121, DAMD 17-97-1-7014, and DAMD 17-99-1-9291.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom reprint request should be addressed: Dept. of Cell Biology
and Anatomy, University of Miami Medical School, 1600 N.W. 10th Ave.,
Miami, FL 33136. Tel.: 305-243-6985; Fax: 305-545-7166; E-mail:
Lbourgui@mednet.med.miami.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
HA, hyaluronic acid;
PHn, pleckstrin homology;
PHc, PH domain located at the COOH-terminal
region of the molecule;
CC, coiled coil region;
Ex, extra region;
CBP, calmodulin-binding peptide;
GFP, green fluorescent protein;
GST, glutathione S-transferase;
PBS, phosphate-buffered saline;
PCR, polymerase chain reaction;
GTP
S, guanosine
5'-3-O-(thio)triphosphate;
Rh, rhodamine;
FITC, fluorescein
isothiocyanate.
 |
REFERENCES |
| 1.
|
Lesley, J.,
Hyman, R.,
and Kincade, P. W.
(1993)
Adv. Immunol.
54,
271-335[Medline]
[Order article via Infotrieve]
|
| 2.
|
Picker, L. J.,
Nakache, M.,
and Butcher, E. C.
(1989)
J. Cell Biol.
109,
927-937[Abstract/Free Full Text]
|
| 3.
|
Bourguignon, L. Y. W.,
Lokeshwar, V. B.,
He, J.,
Chen, X.,
and Bourguignon, G. J.
(1992)
Mol. Cell. Biol.
12,
4464-4471[Abstract/Free Full Text]
|
| 4.
|
Zhu, D.,
and Bourguignon, L. Y. W.
(1996)
Oncogene
12,
2309-2314[Medline]
[Order article via Infotrieve]
|
| 5.
|
Brown, T. A.,
Bouchard, T.,
St. John, T.,
Wayner, E.,
and Carter, W. G.
(1991)
J. Cell Biol.
113,
207-221[Abstract/Free Full Text]
|
| 6.
|
Bourguignon, L. Y. W.
(1996)
Curr. Topics Membr.
43,
293-312
|
| 7.
|
Stamenkovic, I.,
Amiot, M.,
Pesando, J. M.,
and Seed, B.
(1991)
EMBO J.
10,
343-347[Medline]
[Order article via Infotrieve]
|
| 8.
|
Screaton, G. R.,
Bell, M. V.,
Jackson, D. G.,
Cornelis, F. B.,
Gerth, U.,
and Bell, J. I.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
12160-12164[Abstract/Free Full Text]
|
| 9.
|
Bennett, K. L.,
Jackson, D. G.,
Simon, J. C.,
Tanczos, E.,
Peach, R.,
Modrell, B.,
Stamenkivic, I.,
Plowman, G.,
and Aruffo, A.
(1995)
J. Cell Biol.
128,
687-698[Abstract/Free Full Text]
|
| 10.
|
Jackson, D. G.,
Bell, J. I.,
Dickinson, R.,
Timans, J.,
Shields, J.,
and Whittle, N.
(1995)
J. Cell Biol.
128,
673-685[Abstract/Free Full Text]
|
| 11.
|
Jalkanen, S. P.,
and Jalkanen, M.
(1992)
J. Cell Biol.
116,
817-825[Abstract/Free Full Text]
|
| 12.
|
Lokeshwar, V. B.,
and Bourguignon, L. Y. W.
(1991)
J. Biol. Chem.
266,
17983-17989[Abstract/Free Full Text]
|
| 13.
|
Dall, P.,
Heider, K.-H.,
Sinn, H-P,
Skroch-Angel, P.,
Adolf, G.,
Kaufmann, M,
Herrlich, P.,
and Ponta, H.
(1995)
Int. J. Cancer
60,
471-477[Medline]
[Order article via Infotrieve]
|
| 14.
|
Iida, N.,
and Bourguignon, L. Y. W.
(1995)
J. Cell. Physiol.
162,
127-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Kaufmann, M.,
Meider, K. H.,
Sinn, H. P.,
von Minckwitz, G.,
Ponta, H.,
and Herrlich, P.
(1995)
Lancet
345,
615-619[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Rodriguez, C.,
Monges, G.,
Rouanet, P.,
Dutrillaux, B.,
Lefrancois, D.,
and Theillet, C.
(1995)
Int. J. Cancer
64,
347-354[Medline]
[Order article via Infotrieve]
|
| 17.
|
Kalish, E.,
Iida, N.,
Moffat, E. L.,
and Bourguignon, L. Y. W.
(1999)
Front. Biosci.
4,
1-8
|
| 18.
|
Bourguignon, L. Y. W.,
Zhu, D.,
and Zhu, H. B.
(1998)
Front. Biosci.
3,
637-649
|
| 19.
|
Bourguignon, L. Y. W.,
Iida, N.,
Welsh, C. F.,
Zhu, D.,
Krongrad, A.,
and Pasquale, D.
(1995)
J. Neuro-Oncol.
26,
201-208 |